Evaluation of inpatient pneumococcal vaccination rate among adult patients with diabetes in a tertiary care teaching hospital in Saudi Arabia
DOI:
https://doi.org/10.1080/20573316.2018.1439662Keywords:
Evaluation, inpatient, pneumococcal, vaccination, diabetesAbstract
Background: Diabetes mellitus was found to be one of the most common comorbidities for pneumococcal diseases. Pneumococcal vaccinations can reduce morbidity and mortality in this patient population. The purpose of this study was to estimate pneumococcal vaccination rate of these populations in inpatient hospital setting.
Materials and methods: We performed a retrospective chart review involving adult patients with diabetes who were admitted to King Abdulaziz Medical City (KAMC) in Riyadh, Saudi Arabia between the period of March 2016 and March 2017.
Results: A total of 1087 eligible patients were included. The overall vaccination rate for pneumococcus was 1.6% among the vaccine-eligible subjects. The most common risk factors were older age (65 years old or over – 53.9%), chronic renal failure (28.2%) and chronic heart failure (27%), respectively. The majority of the patients in this study were eligible for pneumococcal vaccine (77.6%) due to one or more risk factor other than diabetes mellitus. The mean number of other risk factors other than diabetes mellitus was 1.5 (SD 1.1, 95% CI 1.39–1.53). None of the included patients had documentation on pneumococcal vaccination status.
Conclusion: The pneumococcal vaccine coverage rates among hospitalised patients with diabetes were low in a tertiary care teaching hospital in Saudi Arabia. Further studies are needed to assess the impact of electronic interventions in promoting vaccination assessment and administration among patients with diabetes.
Downloads
References
Pneumococcal disease. World Health Organization. [online] Available from: http://www.who.int/ith/diseases/pneumococcal/en/ [Accessed 21 Jan. 2018]
Kupronis BA, Richards CL Jr, Whitney CG. Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community. J Am Geriatr Soc. 2003;51:1520–5. doi: 10.1046/j.1532-5415.2003.51501.x
World Population Prospects The 2015 Revision Key Findings and Advance Tables. 2015. [ebook] p.241. Available from: https://esa.un.org/unpd/wpp/publications/files/key_findings_wpp_2015.pdf [Accessed 20 Jan. 2018]
Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014;20(5):45–51. doi: 10.1111/1469-0691.12461
Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013;369(2):155–63. doi: 10.1056/NEJMoa1209165
Robke JT, Woods M. A decade of experience with an inpatient pneumococcal vaccination program. Am J Health Syst Pharm. 2010;67(2):148–52. doi: 10.2146/ajhp080638
Myint T, Madhava H, Balmer P, Christopoulou D, Attal S, Menegas D, et al. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther. 2013;30(2):127–51. doi: 10.1007/s12325-013-0007-6
Moore M, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–9. doi: 10.1016/S1473-3099(14)71081-3
Daniels C, Rogers P, Shelton C. A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens. J Pediatr Pharmacol Ther. 2016;21(1): 27–35.
Black S, Lieu TA, Ray GT, Capra A, Shinefield HR. Assessing costs and cost effectiveness of pneumococcal disease and vaccination within Kaiser Permanente. Vaccine. 2000;19(Suppl. 1):S83–6. doi: 10.1016/S0264-410X(00)00284-X
Cho BH, Stoecker C, Link-Gelles R, Moore MR. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions. Vaccine. 2013;31(50):6011–21. doi: 10.1016/j.vaccine.2013.10.024
Nirmal J, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med. 1999;341:1906–12. doi: 10.1056/NEJM199912163412507
Seminog O, Goldacre MJ. Risk of pneumonia and pneumococcal disease in people hospitalized with diabetes mellitus: English record-linkage studies. Diabet Med. 2013;30(12):1412–9. doi: 10.1111/dme.12260
Kyaw MH, Rose Jr CE, Fry AM, Singleton JA., Moore Z, Zell ER, et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005;192:377–86. doi: 10.1086/431521
Pneumococcal Vaccine Recommendations. Centers for disease control and prevention. [online]. Available from: https://www.cdc.gov/vaccines. [Accessed 12 Jan. 2018].
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Cheng AY. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diab. 2013;37(sup 1):S1–S3.
American diabetes association standards of medical care in diabetes. Diabetes Care. 2017;40(sup 1):S1–S138.
Al-Hajjaj MS, Alharbi NS, Zeitouni MO, Idrees MM, Al-Barrak AM, Al-Moamary MS, et al. The Saudi Thoracic Society pneumococcal vaccination guidelines-2016. Ann Thorac Med. 2016;11(2):93–102. doi: 10.4103/1817-1737.180030
Al-Nozha M, Al-Maatouq M, Al-Mazrou Y, Al-Harthi SS, Arafah MR, Khalil MZ, et al. Diabetes mellitus in Saudi Arabia. Saudi Med J. 2004;25:1603–10.
Alqurashi KA, Aljabri KS, Bokhari SA. Prevalence of diabetes mellitus in a Saudi community. Ann Saudi Med. 2011;31(1):19–23. doi: 10.5144/0256-4947.2011.19
Alsenany S, Al Saif A. Incidence of diabetes mellitus type 2 complications among Saudi adult patients at primary health care center. J Phys Ther Sci. 2015;27(6):1727–30. doi: 10.1589/jpts.27.1727
Rubin DJ. Hospital readmission of patients with diabetes. Curr Diab Rep. 2015;15(4):504. doi: 10.1007/s11892-015-0584-7
Nowalk MP, Middleton DB, Zimmerman RK, Hess MM, Skledar SJ, Jacobs MA. Increasing pneumococcal vaccination rates among hospitalized patients. Infect Control Hosp Epidemiol. 2003;24(7):526–31. doi: 10.1086/502240
Smith JG, Metzger NL. Evaluation of pneumococcal vaccination rates after vaccine protocol changes and nurse education in a tertiary care teaching hospital. J Manag Care Pharm. 2011;17(9):701–8.
Williams WW, Lu PJ, O’Halloran A, Kim DK, Grohskopf LA, Pilishvili T, et al. Surveillance of vaccination coverage among adult populations—United States, 2015. MMWR Surveill Summ. 2017;66(11):1–28. doi: 10.15585/mmwr.ss6611a1
Wall GC, Van Der Veer JJ, Romine MJ, Yeager SM. Assessment of candidacy for pneumococcal vaccination in intensive care patients. Intensive Crit Care Nurs. 2013;29(4):212–5. doi: 10.1016/j.iccn.2012.10.004
Yang TU, Song JY, Noh JY, Cheong HJ, Kim WJ. Influenza and pneumococcal vaccine coverage rates among patients admitted to a teaching hospital in South Korea. Infect Chemother. 2015;47(1):41. doi: 10.3947/ic.2015.47.1.41
Brownfield E, Marsden JE, Iverson PJ, Zhao Y, Mauldin PD, Moran WP. Point of care experience with pneumococcal and influenza vaccine documentation among persons aged ≥65 years: high refusal rates and missing information. Am J Infect Control. 2012;40:672–4. doi: 10.1016/j.ajic.2011.12.006
Rees S, Stevens L, Drayton J, Engledow N, Sanders J. Improving inpatient pneumococcal and influenza vaccination rates. J Nurs Care Qual. 2011;26:358–63. doi: 10.1097/NCQ.0b013e31820e0e8c
Kishel JJ, Maguire M, Pankratz L, Julian K. Implementing an electronically based, nurse-driven pneumococcal vaccination protocol for inpatients. Am J Health Syst Pharm. 2009;66:1304–8. doi: 10.2146/080147
Fiks AG, Hunter KF, Localio AR, Grundmeier RW, Bryant-Stephens T, Luberti AA, et al. Impact of electronic health record-based alerts on influenza vaccination for children with asthma. Pediatr. 2009;124(1):159–69. doi: 10.1542/peds.2008-2823
Immunization, MOH. Kingdom of Saudi Arabia — Ministry of Health Portal. [online]. Available from: https://www.moh.gov.sa/en/eServices/Pages/VaccinationsDescription.aspx. [Accessed 20 Jan. 2018]
Stockwell MS, Kharbanda EO, Martinez RA, Vargas CY, Vawdrey DK, Camargo S. Effect of a text messaging intervention on influenza vaccination in an urban, low-income pediatric and adolescent population: a randomized controlled trial. JAMA. 2012;307(16):1702–8. doi: 10.1001/jama.2012.502
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Foundation of European Nurses in Diabetes
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
